• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lung Injury - Pipeline Review, H2 2012 Product Image

Lung Injury - Pipeline Review, H2 2012

  • ID: 2298696
  • October 2012
  • 95 pages
  • Global Markets Direct

Lung Injury – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lung Injury - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Injury. Lung Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Injury.
- A review of the Lung Injury products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Lung Injury Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Lung Injury 10
Lung Injury Therapeutics under Development by Companies 12
Lung Injury Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Lung Injury Therapeutics – Products under Development by Companies 20
Lung Injury Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Lung Injury Therapeutics Development 22
GlaxoSmithKline plc 22
Quark Pharmaceuticals, Inc. 23
Discovery Laboratories, Inc. 24
Silence Therapeutics plc. 25
Merck KGaA 26
REVOTAR Biopharmaceuticals AG 27
Altor BioScience Corporation 28
Mondobiotech Holding AG 29
Implicit Bioscience Limited 30
KYORIN Pharmaceutical Co., Ltd. 31
Ikaria Inc. 32
Faron Pharmaceuticals, Ltd. 33
Lung Injury – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 41
SB-681323 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lucinactant - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ALT-836 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Respiratory And Inflammatory Diseases Program - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
bimosiamose disodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
IK-6002 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KRP-109 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GSK-2586881 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
N-acetylcysteine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
calfactant - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Human Albumin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
hetastarch - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Atu-111 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
interferon beta - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
L-citrulline - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
acetylcysteine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
aspirin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
insulin human - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rosuvastatin calcium - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Atu-134 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
methylprednisolone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ulinastatin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Furosemide + Albumin + Norepinephrine + Vasopressin + Phenylephrine + Epinephrine + Dobutamine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 70
GSK-1995057 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AS-605240 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 73
aviptadil - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DasKloster-014101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
aspirin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Nebulized Hypertonic Saline - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
isoflurane - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Lung Injury Therapeutics – Drug Profile Updates 79
Lung Injury Therapeutics – Discontinued Products 85
Lung Injury Therapeutics - Dormant Products 86
Lung Injury – Product Development Milestones 87
Featured News & Press Releases 87
Sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And US Government Agencies To Assess KL(4) Surfactant Utility In Acute Lung Injury 87
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 88
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 88
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 89
Nov 08, 2011: Silence Provides Development Update Of Atu134 90
Oct 25, 2011: APEPTICO Successfully Completes Phase I Trial With AP301 In Oedematous Respiratory Failure 90
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 91
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease 91
Jun 01, 2011: BARDA Funds Development Of Drug To Prevent Radiation Lung Injury 92
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95

List of Tables
Number of Products Under Development for Lung Injury, H2 2012 10
Products under Development for Lung Injury – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
GlaxoSmithKline plc, H2 2012 22
Quark Pharmaceuticals, Inc., H2 2012 23
Discovery Laboratories, Inc., H2 2012 24
Silence Therapeutics plc., H2 2012 25
Merck KGaA, H2 2012 26
REVOTAR Biopharmaceuticals AG, H2 2012 27
Altor BioScience Corporation, H2 2012 28
Mondobiotech Holding AG, H2 2012 29
Implicit Bioscience Limited, H2 2012 30
KYORIN Pharmaceutical Co., Ltd., H2 2012 31
Ikaria Inc., H2 2012 32
Faron Pharmaceuticals, Ltd., H2 2012 33
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 40
Lung Injury Therapeutics – Drug Profile Updates 79
Lung Injury Therapeutics – Discontinued Products 85
Lung Injury Therapeutics – Dormant Products 86

List of Figures
Number of Products under Development for Lung Injury, H2 2012 10
Products under Development for Lung Injury – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Route of Administration, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Molecule Type, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 39

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos